Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Preventing Infectious Complications of Glucocorticoids
Description
The talk focuses on preventing infectious complications related to glucocorticoid use, outlining risk factors and strategies for avoidance. It addresses the influence of glucocorticoids on both adaptive and innate immunity, which increases the risk of various infections. Specific case studies, such as a woman with granulomatosis and pulmonary complications, illustrate key concepts. For Pneumocystis pneumonia (PCP), a higher risk is identified in patients receiving over 20 mg/day of Prednisone for four weeks in combination with other immunosuppressive agents. Prophylaxis is typically recommended under additional risk factors like organ transplants or certain cancers. Detailed risk assessments indicate that most dermatology patients have a lower incidence of such infections, leading to a careful consideration of prophylaxis necessity. Additionally, patients on high-dose steroids should be screened for tuberculosis, hepatitis, and HIV, especially when initiating biologics. The use of vaccines is also discussed, emphasizing the need to avoid live vaccines during high-dose steroid treatments while underscoring the importance of inactivated vaccines administered prior to immunosuppression. The summary encapsulates guidelines for screening and prophylaxis measures, advocating for tailored patient care based on immunosuppressive therapy and existing health conditions.
View moreConclusions
- Glucocorticoids significantly affect both adaptive and innate immunity, increasing the risk of infections in patients.
- The risk of Pneumocystis pneumonia is notably tied to a total dose of more than 20 mg/day of prednisone for a duration of over four weeks.
- Chronic use of steroids alone does not generally increase the population risk for Pneumocystis pneumonia unless combined with other immunosuppressive agents.
- Patients with additional risk factors such as hematopoietic malignancies, organ transplants, or those undergoing intensive immunosuppression should receive prophylaxis for Pneumocystis pneumonia.
- Dermatology patients typically have a lower risk of Pneumocystis pneumonia, but those with diseases like granulomatosis with polyangiitis may require prophylaxis.
- Vaccination against pneumococcal pneumonia and zoster is recommended for patients on long-term glucocorticoids.
- Screening for tuberculosis, hepatitis B, hepatitis C, and HIV is crucial for patients expected to receive high doses of steroids for extended periods.
- Inactivated vaccines are safe for those on steroids, while live vaccines should be avoided during immunosuppression.
- Patients must be counseled about the risks of infections and the importance of vaccination prior to steroid therapy.
- JAMA. 2023 Jul 11;330(2):182-183.
- Mayo Clin Proc. 2007;82:1052-9.
- J Am Acad Dermatol. 2010;63:815-23.
- J Am Acad Dermatol. 2010;62:957-61.
- JAMA. 2023 Nov 21;330(19):1908-1909.
- Arthritis Rheum. 2006;55:19-26.
- ACR Open Rheumatol. 2020;2(6):357.
- J Am Acad Dermatol. 2017 Feb;76(2):191-198.